FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029608533> ?p ?o ?g. }

• W3029608533 endingPage "274" @default.
• W3029608533 startingPage "269" @default.
• W3029608533 abstract "ObjectiveTo observe the clinical features and visual prognostic factors of ethambutol-induced optic neuropathy (EON).MethodsA cohort study. Twenty-four inpatients (46 eyes) identified as EON in Neuro-Ophthalmology Department of Chinese PLA General Hospital from January 2014 to December 2017 were enrolled, including 14 males (26 eyes) and 10 females (20 eyes) with a ratio of 1.4/1 male/female. The average age was 42.79±15.12 years and the average weight was 62.46±12.31 kg. The average time duration between oral administration of ethambutol and occurrence of EON was 9.94±16.49 months. The average time of ethambutol duration was 7.06±11.68 months, with an average accumulative dose of 156.7±1 779.0 g and the average daily dose of 15.07±8.95 mg/(kg·d). All patients were tested with visual acuity, fundus photos, colour vision, OCT, visual field, VEP, orbital MRI and the gene of OPA1 and mitochondrial deoxyribonucleic acid(mtDNA). All the patients accepted drug withdrawal immediately after diagnosis, and were given the treatment of systemic nerve nutrition and improvement of microcirculation for 2 weeks. The time of follow-up was more than 12 months. According to whether the visual acuity (VA) in any of eyes was over than 0.1 at the last follow- up, all the patients were divided into two groups: the bad VA group (VA less than or equal to 0.1) and the better VA group (VA over than 0.1) group. The χ2 test and Fisher's exact probabilistic method test were used to compare the counting data between groups, and the Wlincox rank sum test was used to compare the measurement data. Multiple factors of VA outcome between the patients with bad or better va were analyzed by logistic regression.ResultsThirty eyes (65.2%) had VA less than or equal to 0.1 and 5 eyes (10.9%) had VA over than 0.5 at EON onset. The VA of the rest 11 eyes (23.9%) was higher than 0.1 and lower than 0.5. At the last follow- up, 20 eyes (43.5%) had VA less than or equal to 0.1 and 9 eyes (19.6%) had VA over than 0.5, the VA of the rest 17 eyes (36.9%) was higher than 0.1 and lower than 0.5. Fundus examination revealed 7 eyes (15.3%) with optic disc edema. OCT revealed significant loss of the retinal nerve fiber layer (RNFL) in the affected eyes, mainly in the temporal RNFL of the optic disc. All patients had dyschromasia, mainly in distinguishing the color of red and green. The types of visual field defect was as following: central dark spot (52.2%), diffuse visual acuity decreased (30.4%), temporal hemianopsia (17.4%). Orbital MRI revealed that 12/24 (50.0%) patients had T2 lesions with T1 enhancement in 6/24 patients (25.0%). Genetic test showed that 4 patients (16.7%) had gene mutation. Among them, there were 2 patients with OPA1 mutation, 1 with mtDNA 14340 point mutation and 1 with the mtDNA 11778 point mutation. Thirteen patients showed better VA outcomes (over than 0.1) while 11 showed bad VA outcomes after discontinuation of ethambutol. Between the better VA group and the bad VA group, there were statistically significant differences in the daily dose of ethambutol and gene mutation(P=0.031, 0.023). The daily dose was related to visual prognosis of EON while only the daily dose of more than 18 mg/(kg·d) may lead to bad VA outcomes according to the logistic analysis (95% CI 0.007-0.736, OR=0.069, P=0.027).ConclusionsEON may have OPA1 and mtDNA mutation with more bilateral eyes involved and less optic edema, which about 43.5% of the patients showed irreversible visual impact. The daily dose of ethambutol is related to the vision recovery.Key words: Ethambutol/adverse effects; Optic nerve diseases; Disease attributes; Prognosis; Root cause analysis" @default.
• W3029608533 created "2020-06-05" @default.
• W3029608533 creator A5016855487 @default.
• W3029608533 creator A5020778111 @default.
• W3029608533 creator A5063338779 @default.
• W3029608533 creator A5066354580 @default.
• W3029608533 creator A5066496392 @default.
• W3029608533 creator A5087840576 @default.
• W3029608533 date "2020-04-25" @default.
• W3029608533 modified "2023-09-27" @default.
• W3029608533 title "Clinical characteristics and prognostic factors analysis of ethambutol-induced optic neuropathy" @default.
• W3029608533 doi "https://doi.org/10.3760/cma.j.cn511434-20190401-00123" @default.
• W3029608533 hasPublicationYear "2020" @default.
• W3029608533 type Work @default.
• W3029608533 sameAs 3029608533 @default.
• W3029608533 citedByCount "0" @default.
• W3029608533 crossrefType "journal-article" @default.
• W3029608533 hasAuthorship W3029608533A5016855487 @default.
• W3029608533 hasAuthorship W3029608533A5020778111 @default.
• W3029608533 hasAuthorship W3029608533A5063338779 @default.
• W3029608533 hasAuthorship W3029608533A5066354580 @default.
• W3029608533 hasAuthorship W3029608533A5066496392 @default.
• W3029608533 hasAuthorship W3029608533A5087840576 @default.
• W3029608533 hasConcept C118487528 @default.
• W3029608533 hasConcept C126322002 @default.
• W3029608533 hasConcept C141071460 @default.
• W3029608533 hasConcept C142724271 @default.
• W3029608533 hasConcept C2776058522 @default.
• W3029608533 hasConcept C2776228421 @default.
• W3029608533 hasConcept C2776391266 @default.
• W3029608533 hasConcept C2778233873 @default.
• W3029608533 hasConcept C2778257484 @default.
• W3029608533 hasConcept C2778607973 @default.
• W3029608533 hasConcept C2780837183 @default.
• W3029608533 hasConcept C2781069245 @default.
• W3029608533 hasConcept C71924100 @default.
• W3029608533 hasConcept C72563966 @default.
• W3029608533 hasConceptScore W3029608533C118487528 @default.
• W3029608533 hasConceptScore W3029608533C126322002 @default.
• W3029608533 hasConceptScore W3029608533C141071460 @default.
• W3029608533 hasConceptScore W3029608533C142724271 @default.
• W3029608533 hasConceptScore W3029608533C2776058522 @default.
• W3029608533 hasConceptScore W3029608533C2776228421 @default.
• W3029608533 hasConceptScore W3029608533C2776391266 @default.
• W3029608533 hasConceptScore W3029608533C2778233873 @default.
• W3029608533 hasConceptScore W3029608533C2778257484 @default.
• W3029608533 hasConceptScore W3029608533C2778607973 @default.
• W3029608533 hasConceptScore W3029608533C2780837183 @default.
• W3029608533 hasConceptScore W3029608533C2781069245 @default.
• W3029608533 hasConceptScore W3029608533C71924100 @default.
• W3029608533 hasConceptScore W3029608533C72563966 @default.
• W3029608533 hasIssue "04" @default.
• W3029608533 hasLocation W30296085331 @default.
• W3029608533 hasOpenAccess W3029608533 @default.
• W3029608533 hasPrimaryLocation W30296085331 @default.
• W3029608533 hasRelatedWork W2046256438 @default.
• W3029608533 hasRelatedWork W2047404663 @default.
• W3029608533 hasRelatedWork W2077066916 @default.
• W3029608533 hasRelatedWork W2156018975 @default.
• W3029608533 hasRelatedWork W2260969947 @default.
• W3029608533 hasRelatedWork W2262995848 @default.
• W3029608533 hasRelatedWork W2280989331 @default.
• W3029608533 hasRelatedWork W2350012504 @default.
• W3029608533 hasRelatedWork W2365123002 @default.
• W3029608533 hasRelatedWork W2403467248 @default.
• W3029608533 hasRelatedWork W2413619572 @default.
• W3029608533 hasRelatedWork W2726575156 @default.
• W3029608533 hasRelatedWork W2790165227 @default.
• W3029608533 hasRelatedWork W2943567605 @default.
• W3029608533 hasRelatedWork W3044428641 @default.
• W3029608533 hasRelatedWork W3082823603 @default.
• W3029608533 hasRelatedWork W3135766922 @default.
• W3029608533 hasRelatedWork W3185965473 @default.
• W3029608533 hasRelatedWork W3208753170 @default.
• W3029608533 hasRelatedWork W3211076071 @default.
• W3029608533 hasVolume "36" @default.
• W3029608533 isParatext "false" @default.
• W3029608533 isRetracted "false" @default.
• W3029608533 magId "3029608533" @default.
• W3029608533 workType "article" @default.